RU2644346C2 - Система полицистронной экспрессии для бактерий - Google Patents

Система полицистронной экспрессии для бактерий Download PDF

Info

Publication number
RU2644346C2
RU2644346C2 RU2013157300A RU2013157300A RU2644346C2 RU 2644346 C2 RU2644346 C2 RU 2644346C2 RU 2013157300 A RU2013157300 A RU 2013157300A RU 2013157300 A RU2013157300 A RU 2013157300A RU 2644346 C2 RU2644346 C2 RU 2644346C2
Authority
RU
Russia
Prior art keywords
promoter
gene
lactic acid
genes
endogenous
Prior art date
Application number
RU2013157300A
Other languages
English (en)
Russian (ru)
Other versions
RU2013157300A (ru
Inventor
Клаас ВАНДЕНБРОУКЕ
ХЮНЕГЕМ Каролин ВАН
Лотхар СТЕЙДЛЕР
Original Assignee
Интрексон Актобиотикс Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Интрексон Актобиотикс Н.В. filed Critical Интрексон Актобиотикс Н.В.
Publication of RU2013157300A publication Critical patent/RU2013157300A/ru
Application granted granted Critical
Publication of RU2644346C2 publication Critical patent/RU2644346C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
RU2013157300A 2011-06-01 2012-06-01 Система полицистронной экспрессии для бактерий RU2644346C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11168495.7 2011-06-01
EP11168495 2011-06-01
EP11173588 2011-07-12
EP11173588.2 2011-07-12
PCT/EP2012/060431 WO2012164083A1 (en) 2011-06-01 2012-06-01 Polycistronic expression system for bacteria

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2018102374A Division RU2766157C2 (ru) 2011-06-01 2012-06-01 Система полицистронной экспрессии для бактерий

Publications (2)

Publication Number Publication Date
RU2013157300A RU2013157300A (ru) 2015-07-20
RU2644346C2 true RU2644346C2 (ru) 2018-02-08

Family

ID=46354175

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2013157300A RU2644346C2 (ru) 2011-06-01 2012-06-01 Система полицистронной экспрессии для бактерий
RU2018102374A RU2766157C2 (ru) 2011-06-01 2012-06-01 Система полицистронной экспрессии для бактерий

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2018102374A RU2766157C2 (ru) 2011-06-01 2012-06-01 Система полицистронной экспрессии для бактерий

Country Status (13)

Country Link
US (3) US9920324B2 (cg-RX-API-DMAC10.html)
EP (2) EP2714912B1 (cg-RX-API-DMAC10.html)
JP (3) JP6175428B2 (cg-RX-API-DMAC10.html)
KR (1) KR102066292B1 (cg-RX-API-DMAC10.html)
CN (2) CN103562390B (cg-RX-API-DMAC10.html)
AU (2) AU2012264589B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013030824A8 (cg-RX-API-DMAC10.html)
CA (2) CA2837634C (cg-RX-API-DMAC10.html)
DK (1) DK2714912T3 (cg-RX-API-DMAC10.html)
ES (1) ES2676877T3 (cg-RX-API-DMAC10.html)
HU (1) HUE039577T2 (cg-RX-API-DMAC10.html)
RU (2) RU2644346C2 (cg-RX-API-DMAC10.html)
WO (1) WO2012164083A1 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2714912B1 (en) 2011-06-01 2018-05-02 Intrexon Actobiotics NV Polycistronic expression system for bacteria
US9593339B1 (en) * 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP3034610A1 (en) * 2013-08-13 2016-06-22 The Kitasato Institute Novel terpenoid compound and method for producing same
ES2884948T3 (es) 2014-12-03 2021-12-13 Azusapharma Sciences Inc Plásmido de coexpresión
EP3237622B1 (en) 2014-12-23 2021-02-24 Ilya Pharma AB Methods for wound healing
AU2016261279B2 (en) 2015-05-10 2020-12-10 Ventana Medical Systems, Inc. Compositions and methods for simultaneous inactivation of alkaline phosphatase and peroxidase enzymes during automated multiplex tissue staining assays
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7292877B2 (ja) 2016-01-14 2023-06-19 イントレクソン・アクトバイオテイクス・エヌブイ １型糖尿病を処置するための組成物および方法
US10858663B2 (en) 2016-09-02 2020-12-08 Intrexon Actobiotics N.V. Genetically modified bacteria stably expressing IL-10 and insulin
KR102469701B1 (ko) * 2016-09-13 2022-11-22 인트랙슨 액토바이오틱스 엔.브이. 점막부착성 미생물
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
GB201906775D0 (en) * 2019-05-14 2019-06-26 Res & Innovation Uk Synthetic genome
CA3156035A1 (en) 2019-09-27 2021-04-01 Intrexon Actobiotics Nv D/B/A Precigen Actobio Treatment of celiac disease
WO2024003873A1 (en) 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569604A1 (en) * 1992-04-07 1993-11-18 Societe Des Produits Nestle S.A. Integrative gene-expression in Streptococcus salivarius ssp.thermophilus
WO2001062944A2 (en) * 2000-02-24 2001-08-30 Siga Pharmaceuticals, Inc. Intergenic and intragenic integration sites for foreign gene expression in recombinant s. gordonii strains
WO2005071088A2 (en) * 2003-12-24 2005-08-04 Cerus Corporation Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
US20050249748A1 (en) * 2003-12-24 2005-11-10 Dubensky Thomas W Jr Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
RU2311929C2 (ru) * 2001-12-11 2007-12-10 Сосьете Де Продюи Нестле С.А. Применение микроорганизмов для направленной доставки веществ к специфическим частям кишечника

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB227835A (en) 1924-01-15 1925-04-09 Harry Odell Improvements in feeding mechanism for embossing and other printing presses
JPS58116498A (ja) 1981-12-28 1983-07-11 Takeda Chem Ind Ltd Ｉｌ‐２をコードする新規伝令ｒｎａの製造法
EP0091539B2 (en) 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
JPH01196296A (ja) * 1988-01-29 1989-08-08 Toray Ind Inc 動物細胞用発現ベクター
US4919918A (en) 1988-03-14 1990-04-24 Spectrum Consumer Products Co., Inc. Non-alcoholic mouthwash
US5972685A (en) 1988-07-21 1999-10-26 Iowa State University Research Foundation, Inc. Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration
GB9006400D0 (en) 1990-03-22 1990-05-23 Ciba Geigy Ag Bacterial vectors
WO1992014837A1 (en) 1991-02-14 1992-09-03 The General Hospital Corporation Intestinal trefoil proteins
US6221840B1 (en) 1991-02-14 2001-04-24 The General Hospital Corporation Intestinal trefoil proteins
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
GB9126306D0 (en) 1991-12-11 1992-02-12 Unilever Plc Mouthwash compositions
EP0628083A1 (en) 1992-02-27 1994-12-14 Microbial Technics Limited Heterologous gene expression in lactococcus, and the expression products therefrom
US5223285A (en) 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5700782A (en) 1993-05-28 1997-12-23 Abbott Laboratories Enteral nutritional product
WO1996032486A1 (en) 1995-04-11 1996-10-17 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method for the construction of vectors for lactic acid bacteria like lactobacillus such that the bacteria can efficiently express, secrete and display proteins at the surface
US5695746A (en) 1995-07-28 1997-12-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Liquid dentifrice with mouthwash fresh taste
GB9521568D0 (en) 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
US6348187B1 (en) 1996-01-24 2002-02-19 Warner-Lambert Company Peroxide/essential oils containing mouthwash compositions and two-part mouthwash systems
GB9611364D0 (en) 1996-05-31 1996-08-07 Smithkline Beecham Plc Composition
ES2197364T3 (es) 1996-09-18 2004-01-01 Erling Johansen Baño bucal comprendiendo iones de calcio y fosfato en solucion sobresaturada.
US5869118A (en) 1996-11-13 1999-02-09 Abbott Laboratories Gellan gum to improve physical stability of liquid nutritional products
US6171611B1 (en) 1997-11-12 2001-01-09 Dante J. Picciano Iodine-containing nasal moisturizing saline and mouthwash solutions
US5897872A (en) 1997-11-12 1999-04-27 Picciano; Dante J. Iodine-containing nasal moisturizing saline solution
WO2000018377A1 (en) 1998-09-28 2000-04-06 Warner-Lambert Company Enteric and colonic delivery using hpmc capsules
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
EP1123314B1 (en) 1998-10-20 2004-02-18 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Use of a cytokine-producing lactococcus strain to treat colitis
CA2378143A1 (en) 1999-06-30 2001-01-11 Societe Des Produits Nestle S.A. The lactose operon of lactobacillus delbrueckii and its use for controlling gene transcription and/or expression in bacterial cells
ES2272311T3 (es) 1999-07-05 2007-05-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Suministro de peptidos trebol.
US7029842B2 (en) * 2000-04-07 2006-04-18 Novozymes A/S Signal sequence trapping
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2446776C (en) 2001-05-03 2011-07-12 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Self-containing lactococcus strain
AU2003247881A1 (en) 2002-07-08 2004-01-23 Joe S. Wilkins Jr. Antibacterial formulations
AU2003298291A1 (en) 2002-11-15 2004-06-15 Universiteit Gent Self-containing lactobacillus strain
WO2004069177A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
EP1493816A1 (en) * 2003-07-02 2005-01-05 Friesland Brands B.V. Methods and means for regulating gene expression
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
KR20070003934A (ko) 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
US7495092B2 (en) * 2005-01-14 2009-02-24 North Carolina State University Compositions comprising promoter sequences and methods of use
US7764366B2 (en) 2006-07-11 2010-07-27 Besi North America, Inc. Robotic die sorter with optical inspection system
JP2009544679A (ja) * 2006-07-25 2009-12-17 ザ ユニヴァーシティー コート オブ ザ ユニヴァーシティー オブ ダンディー 異常な細胞増殖に関連する疾患の治療におけるレチノイド及び小分子のＮｒｆ２アンタゴニストとしての使用
CN101605900B (zh) * 2007-01-12 2014-04-23 阿克图杰尼斯公司 乳球菌启动子和其用途
ES2425385T3 (es) 2009-04-30 2013-10-15 Actogenix N.V. Crioprotectores para la liofilización de las bacterias de ácido láctico
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
US9669071B2 (en) 2011-03-11 2017-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating T lymphocytes with IL-2
EP2714912B1 (en) 2011-06-01 2018-05-02 Intrexon Actobiotics NV Polycistronic expression system for bacteria
EP2753362A4 (en) 2011-09-08 2015-04-15 Univ Florida MATERIALS AND METHOD FOR MODULATING IMMUNE SYSTEM REACTIONS
JP7292877B2 (ja) 2016-01-14 2023-06-19 イントレクソン・アクトバイオテイクス・エヌブイ １型糖尿病を処置するための組成物および方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569604A1 (en) * 1992-04-07 1993-11-18 Societe Des Produits Nestle S.A. Integrative gene-expression in Streptococcus salivarius ssp.thermophilus
WO2001062944A2 (en) * 2000-02-24 2001-08-30 Siga Pharmaceuticals, Inc. Intergenic and intragenic integration sites for foreign gene expression in recombinant s. gordonii strains
RU2311929C2 (ru) * 2001-12-11 2007-12-10 Сосьете Де Продюи Нестле С.А. Применение микроорганизмов для направленной доставки веществ к специфическим частям кишечника
WO2005071088A2 (en) * 2003-12-24 2005-08-04 Cerus Corporation Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
US20050249748A1 (en) * 2003-12-24 2005-11-10 Dubensky Thomas W Jr Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRUCKNER R, Gene raplacement in Staphylococcus carnosus and Staphylococcus xylosus, FEMS Microbiol Lett, 1997 Jun 1, Vol.151, N.1, pp.1-8. *
BRUCKNER R, Gene raplacement in Staphylococcus carnosus and Staphylococcus xylosus, FEMS Microbiol Lett, 1997 Jun 1, Vol.151, N.1, pp.1-8. SABINE DOBINSKY et al., Influence of Tn917 Insertion on Transcription of the icaADBC Operon in Six Biofilm-Negative Transposon Mutants of Staphylococcus epidermidis, Plasmid, 2002, Vol.47, pp.10-17. *
SABINE DOBINSKY et al., Influence of Tn917 Insertion on Transcription of the icaADBC Operon in Six Biofilm-Negative Transposon Mutants of Staphylococcus epidermidis, Plasmid, 2002, Vol.47, pp.10-17. *

Also Published As

Publication number Publication date
ES2676877T3 (es) 2018-07-25
JP2014518062A (ja) 2014-07-28
KR20140027405A (ko) 2014-03-06
US9920324B2 (en) 2018-03-20
EP2714912A1 (en) 2014-04-09
KR102066292B1 (ko) 2020-01-14
EP3360967B1 (en) 2020-09-09
US10988770B2 (en) 2021-04-27
US20140105863A1 (en) 2014-04-17
AU2012264589B2 (en) 2017-02-16
BR112013030824A8 (pt) 2018-04-03
JP2017200477A (ja) 2017-11-09
JP6175428B2 (ja) 2017-08-02
CN107267546B (zh) 2021-08-17
CN103562390B (zh) 2017-07-18
EP3360967A1 (en) 2018-08-15
US20210163961A1 (en) 2021-06-03
EP2714912B1 (en) 2018-05-02
RU2018102374A3 (cg-RX-API-DMAC10.html) 2021-03-30
AU2017203281A1 (en) 2017-06-08
AU2012264589A1 (en) 2014-01-09
CN107267546A (zh) 2017-10-20
WO2012164083A1 (en) 2012-12-06
JP2021097671A (ja) 2021-07-01
HUE039577T2 (hu) 2019-01-28
DK2714912T3 (en) 2018-08-13
CA3136084A1 (en) 2012-12-06
HK1244033A1 (zh) 2018-07-27
AU2017203281B2 (en) 2019-01-03
RU2766157C2 (ru) 2022-02-08
JP6867866B2 (ja) 2021-05-12
CA2837634C (en) 2021-12-14
CN103562390A (zh) 2014-02-05
CA2837634A1 (en) 2012-12-06
HK1257050A1 (en) 2019-10-11
RU2018102374A (ru) 2019-02-21
BR112013030824A2 (pt) 2016-12-06
RU2013157300A (ru) 2015-07-20
US20180187203A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
US10988770B2 (en) Polycistronic expression system for bacteria
JP5584470B2 (ja) ラクトコッカスプロモーター及びその使用
CA2738781C (en) Reduced colonization of microbes at the mucosa
CA2787787A1 (en) Transformation plasmid
HK1257050B (en) Polycistronic expression system for bacteria
HK1244033B (en) Polycistronic expression system for bacteria
Remaut et al. Clinical potential of Lactococcus lactis mediated delivery of human interleukin-10 and trefoil factors

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant